EGFR and cancer: AhR can activate EGFR through both traditional genomic signaling and nongenomic pathways, promoting cancer cell proliferation and resistance to EGFR–TKIs by activating proto-oncogene tyrosine-protein kinase Src (Src) signaling (Ye et al, 2018).